Autoantibodies to amyloid-β and Alzheimer's disease
Article first published online: 6 JUN 2001
Copyright © 2001 Wiley-Liss, Inc.
Annals of Neurology
Volume 49, Issue 6, pages 808–810, June 2001
How to Cite
Hyman, B. T., Smith, C., Buldyrev, I., Whelan, C., Brown, H., Tang, M.-X. and Mayeux, R. (2001), Autoantibodies to amyloid-β and Alzheimer's disease. Ann Neurol., 49: 808–810. doi: 10.1002/ana.1061
- Issue published online: 6 JUN 2001
- Article first published online: 6 JUN 2001
- Manuscript Accepted: 27 MAR 2001
- Manuscript Revised: 23 MAR 2001
- Manuscript Received: 21 FEB 2001
- Unknown funding agency. Grant Numbers: AG08702, AG07232, AG05134, AG08487
Immunization against amyloid-β has been suggested as a possible preventive or therapeutic treatment for Alzheimer's disease. We hypothesized that some individuals may have autoantibodies to amyloid-β and that this may be protective. We analyzed the plasma of 365 individuals, drawn from a larger longitudinal epidemiological study, for the presence of antibodies to amyloid-β. There were detectable but very low levels of anti-amyloid-β antibodies in just over 50% of all samples and modest levels in under 5% of all samples. However, neither the presence nor the level of anti-amyloid-β antibodies correlated with the likelihood of developing dementia or with plasma levels of amyloid-β peptide. These data suggest that low levels of anti-amyloid-β autoantibodies are frequent in the elderly population but do not confer protection against developing dementia.